Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Down 96.6% in February

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 100 shares, a drop of 96.6% from the February 13th total of 2,900 shares. Based on an average daily volume of 10,600 shares, the days-to-cover ratio is presently 0.0 days.

Defence Therapeutics Stock Performance

DTCFF opened at $1.00 on Thursday. Defence Therapeutics has a 12 month low of $0.27 and a 12 month high of $1.32. The company has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $0.52.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.